Subscribe or Manage Preferences
A new paradigm of survivorship care is needed that attempts to balance the patient’s total well-being against the often toxic treatment of the disease, suggests Deborah Korenstein, MD, Director of Clinical Effectiveness, Memorial Hospital, Memorial Sloan Kettering Cancer Center, NY. At the 2016 Cancer Survivorship Symposium, Dr [ Read More ]
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed, according to Joseph Alvarnas, MD, Director of Value-Based Analytics, and Associate Clinical Professor of Hematology and Hematopoietic Cell [ Read More ]
The date of the implementation of the International Classification of Diseases, Clinical Modification (ICD-10-CM, henceforth “ICD-10”), has come and gone, and we have survived what is arguably the most significant change for providers in the history of reporting healthcare services. As the dust settles, [ Read More ]
Linking physicians and patients is a major undertaking, but given the ubiquity of smartphone technology and the rise in app development, the healthcare industry is poised to leverage advances in communication and information exchange. At the 2016 Cancer Survivorship Symposium, Steven J. Katz, MD, MPH, Professor of Medicine and Health [ Read More ]
In 1971, President Richard Nixon declared “war on cancer,” and millions of dollars poured into research for new cures for the disease. However, it was not until the early 1990s that we started to see cancer and its symptoms and side effects become more manageable in the outpatient [ Read More ]
The following clinical trials represent a selection of key clinical trials that are currently recruiting patients with multiple myeloma for inclusion in investigations of new therapies and new regimens of available therapies for patients with multiple myeloma. Each clinical trial [ Read More ]
This is the first part of a 3-part series on improving patient care through innovative approaches to dispensing oral oncolytic drugs in the community practice setting. A little more than 2 years ago, a group of like-minded pharmacists from across [ Read More ]
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination. “The purpose of measurement is [ Read More ]
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study (Friedenreich CM, et al. Eur Urol. 2016 Jan 7. Epub ahead of [ Read More ]
Results from the large, randomized PIVOT clinical trial that were published in 2012 initially showed that at a median follow-up of 19 years, radical prostatectomy neither improved overall survival nor reduced death related to prostate cancer compared with “watchful waiting” [ Read More ]
Idelalisib (Zydelig) reduced the risk for disease progression and death when added to bendamustine (Treanda) plus rituximab (Rituxan) versus bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of a randomized, [ Read More ]
You pay more than your fair share of taxes, so when it comes to your investments, why would you pay more than you absolutely have to? While it may be too late to save taxes on investments you made last [ Read More ]
Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure.1,2 According to the American Cancer Society, more than 26,800 new cases of multiple myeloma were diagnosed in 2015, [ Read More ]
This detailed article of codes related to multiple myeloma is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with multiple myeloma. [ Read More ]